Catalysts · EXEL · CIK 939767 · page 2 of 2

EXEL catalysts and FDA events, page 2.

Updated Snapshot 20261116T222116ZBuilt

The next PDUFA date, the soonest catalysts with their source quotes and the latest FDA decisions are on EXEL PDUFA dates and upcoming catalysts. This page continues the list.

Past catalysts and FDA decisions (continued)

DateDrugCompanyEventIndicationStatusSource
1H 2025Half-year disclosedzanzalintinib (XL092)EXELInterim readout—ScheduledSEC 8-K Exhibit 99.1
1H 2025Half-year disclosedzanzalintinib (XL092)EXELTrial startadvanced NET, regardless of site of originScheduledSEC 8-K Exhibit 99.1
Aug 2024Month disclosedCABOMETYX® (cabozantinib)EXELNDA/BLA accepted—CompletedSEC Form 10-K
Aug 2023Month disclosedCABOMETYX® (cabozantinib)EXELTopline readoutmeasurable, extra-pelvic metastatic castration-resistant prostate cancerPositiveSEC Form 10-Q
July 14, 2022Cabometyx (cabozantinib s-malate)EXELLabel expansion—ApprovedopenFDA Drugs@FDA
September 17, 2021Cabometyx (cabozantinib s-malate)EXELLabel expansion—ApprovedopenFDA Drugs@FDA
January 22, 2021Cabometyx (cabozantinib s-malate)EXELLabel expansion—ApprovedopenFDA Drugs@FDA
April 25, 2016Cabometyx (cabozantinib s-malate)EXELFDA approval—ApprovedopenFDA Drugs@FDA
Every catalyst is quoted from EXEL’s SEC filings, FDA records or ClinicalTrials.gov; each row links its primary source. Dates move; the linked filing is authoritative. Not investment advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.